Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2017 Status changed from not yet recruiting to active, no longer recruiting.